Dual drug loaded superparamagnetic iron oxide nanoparticles for targeted cancer therapy
Introduction
Magnetic nanoparticles (MNPs) are emerging as promising candidates for applications in biomedical research encompassing of drug delivery [1], magnetic resonance imaging [2], cell mechanics [3], hyperthermia [4], tumor progression [5], in vivo tracking of stem cells, nucleic acid and cell separation [6], [7], due to their ultra fine sizes, biocompatibility and superparamagnetic behavior [1], [8]. For biomedical application the MNPs are perfect model for high level of accumulation in the target tissues or organ due to their host cell tropism, biophysical nature [9], and low toxicity [10]. The pharmaceutical drugs are loaded to the surface of the MNPs, which are released at the target site with external localized magnetic field gradient, thereby offering a possibility of nonspecific toxicities by administering lower but more accurately targeted dose [11].
The size and surface charge chemistry of MNPs are predominantly important for monitoring systemic tumor response to drug treatment [12]. The inherent aggregation behavior of MNPs occurring due to the high surface-to-volume ratio and attractive forces between the magnetites is a crucial limiting factor which reduces the intrinsic superparamagnetic properties [13], and triggers the opsonization process [9]. Therefore, to minimize the aggregation, it is essential to engineer the surface of the MNPs. Synthetic and natural polymers (dextran, polyethyleneglycol (PEG), and poly(vinylpyrrolidone) (PVP), streptavidin, poly-l-lysine (PLL), polyethylene imide (PEI) etc.) have been employed to modify the surface of the MNPs [13]. To facilitate the anchoring and attachment of the polymers to MNPs several monomeric species like bisphosphonates [14], dimercaptosuccinic acid [15], and aloxysilane [16], were examined, but these agents could not allocate colloidal stability at physiological pH [17]. Therefore, coating the MNPs with large molecules (polymers or surfactants) containing long-chain hydrocarbons, helps to prevent the aggregation of particles in biological solution for more effective stabilization. [18].
Various research groups mostly use long-chain polymer oleic acid (OA) and its salts [19], for the stabilization of iron oxide nanoparticles. Jain et al. have developed aqueous dispersible oleic acid-pluronic (F-127) stabilized iron oxide nanoparticle, encapsulating hydrophobic drug [1]. However, there is potential concern about the toxic effects of pluronic (F-127), towards human erythrocytes [20], and elevation of cholesterol and triglycerides level in the blood plasma [21]. Consequently, with an aim of achieving colloidal stability of the magnetic nanoparticles without use of any surfactant, a synthetic lipid, glyceryl monooleate (GMO) approved by food and drug administration (FDA) is considered in our study. GMO is an unsaturated monoglyceride amphiphilic lipid [22], used as emulsifier, flavouring agent and excipient for antibiotics. It forms different types of lyotropic liquid crystals which is water and temperature dependant [23] furthermore, its bioadhesiveness, high viscosity property increases the contact time at the targeted tissues providing a platform for sustained release of drugs by slow drug diffusion in solubilized form [24] thus, enhancing the therapeutic efficacy [25] for drug delivery [26]. The heterogeneous structure of GMO in water permits incorporation of hydrophilic and hydrophobic drugs unaffecting the phase structure [27]. GMO has a similar long-chain polymer structure as that of oleic acid (OA), mainly used in the formulation of MNPs. Keeping in view these properties of GMO, we have coated the MNPs with GMO replacing OA.
We hypothesize that, drug loaded GMO-MNPs will be an ideal drug delivery system for the treatment of cancer, where the hydrophobic drug would partition into the GMO coating, providing aqueous dispersibility with no loss of magnetization. Hence, we developed an aqueous based ultrafine stable GMO-MNP formulation for drug delivery without the use of any surfactant. The formulated GMO-MNPs were well characterized by different techniques, such as, transmission electron microscopy (TEM), dynamic laser light scattering (DLS), fourier transmission infrared spectroscopy (FT-IR), superconducting quantum interference device (SQUID), reverse-phase high pressure liquid chromatography (RP-HPLC) for their particle size, zeta potential, magnetization and entrapment efficiency respectively. The cytotoxicity and inflammatory response of the GMO-MNPs was determined through confocal microscopy, tumor necrosis factor (TNF-α) assay by enzyme-linked immunosorbent assay (ELISA) method using human breast carcinoma cell lines (MCF-7). Further, for the conjugation of any peptide or protein, the GMO-MNPs were functionalized with DMSA (2, 3 meso mercapto succinic acid). The targeted therapeutic purpose of the GMO-MNPs was achieved through the conjugation of HER2 antibody.
Section snippets
Materials
Iron (III) chloride hexahydrate (FeCl3.6H2O) pure granulated, 99%, Iron (II) chloride tetrahydrate (FeCl2.4H2O) 99%, ammonium hydroxide, 2, 3 meso mercapto succinic acid (DMSA), tween 80, pluronic F-127, span series, stannous chloride, mercuric chloride, orthophosphoric acid, potassium dichromate and potassium bromide were purchased from Sigma–Aldrich (St. Louis, MO). Glyceryl monooleate was procured from Eastman (Memphis, TN). Lysotracker dye was procured from Invitrogen Corporation, Carlsbad,
Formulation of aqueous dispersible magnetic nanoparticles (MNPs)
Due to the hydrophilicity nature of the native iron oxide particles, they preclude dispersibility in organic solvents. During coating of GMO to the magnetic nanoparticles, GMO gets chemisorbed on the surface of the iron oxide particles. The hydrophobic nature of the GMO makes the GMO coated magnetic particles easily dispersible in the organic solvents. For the utilization of nanoparticles for drug delivery purpose, it is better to have a water dispersible formulation. To get a good water
Discussion
The primary shortcoming of most chemotherapeutic agents is their relative non-specificity and thus potential side effects to healthy tissues. To overcome this problem, magnetic nanoparticle based drug delivery system are implemented, which utilizes the attraction of MNP to an external magnetic field to increase site specific delivery of therapeutic agents [44]. The MNPs have a proven candidacy for its biocompatibility and its wide application in the medical field [45]. Thus, in order to create
Conclusions
Our present investigation demonstrated the distinctiveness of formulated GMO-MNPs which can be aqueous dispersible without the use of any surfactant providing a scope of conjugating various ligands and antibodies for active drug targeting and imaging. With our system, a high payload of hydrophobic drug can be achieved with sustained release of loaded drugs under in vitro condition and exhibiting dose dependant cytotoxicity in MCF-7 cells. Therefore, it can be used as drug loading vehicle for
References (62)
- et al.
A model for cytoplasmic rheology consistent with magnetic twisting cytometry
Biorheology
(1998) - et al.
Heating potential of iron oxides for therapeutic purposes in interventional radiology
Acad Radiol
(2002) - et al.
Isolation of circulating cancer cells from whole blood by immunomagnetic cell enrichment and unenriched immunocytochemistry in vitro
J Urol
(2003) - et al.
Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications
Biomaterials
(2005) - et al.
Nonpolymeric coatings of iron oxide colloids for biological use as magnetic resonance imaging contrast agents
J Colloid Interf Sci
(2001) - et al.
Thiolation of maghemite nanoparticles by dimercaptosuccinic acid
J Colloid Interf Sci
(1997) - et al.
Phosphorylcholine coating of iron oxide nanoparticles
J Colloid Interf Sci
(1999) - et al.
Magnetic nanoparticles in MR imaging and drug delivery
Adv Drug Deliv Rev
(2008) - et al.
Formulation of an oral dosage form utilizing the properties of cubic liquid crystalline phases of glyceryl monooleate
Eur J Pharm Biopharm
(2002) - et al.
In vitro peptide release from liquid crystalline buccal delivery systems
Int J Pharm
(2000)
A novel in situ gel for sustained drug delivery and targeting
Int J Pharm
Development of a rectal nicotine delivery system for the treatment of ulcerative colitis
Int J Pharm
Targeting cancer cells using PLGA nanoparticles surface modified with monoclonal antibody
J Control Rel
Preparation and characterization of hydrophobic superparamagnetic magnetite gel
J Magn Magn Mater
Targeted epidermal growth factor receptor nanoparticle bioconjugates for breast cancer therapy
Biomaterials
Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system
Adv Drug Deliv Rev
Nanotech approaches in drug delivery and imaging
Drug Discovery Today
Preparation, characterisation, and performance of magnetic iron–carbon composite microparticles for chemotherapy
Biomaterials
Magnetic nanoparticles with dual functional properties: drug delivery and magnetic resonance imaging
Biomaterials
Using anti-VEGF McAb and magnetic nanoparticles as double-targeting vector for the radioimmunotherapy of liver cancer
Cancer Lett
Folic acid–Pluronic F127 magnetic nanoparticle clusters for combined targeting, diagnosis, and therapy applications
Biomaterials
Magnetite nanoparticle-loaded anti-HER2 immunoliposomes for combination of antibody therapy with hyperthermia
Cancer Lett
Iron oxide nanoparticles for sustained delivery of anticancer agents
Mol Pharm
Differential conjugation of tat peptide to superparamagnetic nanoparticles and its effect on cellular uptake
Bioconjugate Chem
Magnetodendrimers allow endosomal magnetic labeling and in vivo tracking of stem cells
Nat Biotechnol
Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations
PNAS
Surface modification of gamma-Fe2O3@SiO2 magnetic nanoparticles for the controlled interaction with biomolecules
J Nanosci Nanotechnol
Long-circulating and target-specific nanoparticles: theory to practice
Pharm Rev
Iron oxide MR contrast agents for molecular and cellular imaging
NMR Biomed
Magnetic nanoparticles for drug delivery
Drug Dev Res
Functionalisation of magnetic nanoparticles for applications in biomedicine
J Phys D: Appl Phys
Cited by (364)
Targeted drug release and in vitro anticancer activities of iron oxide@folic acid/chitosan-based nano-niosomes
2024, Colloids and Surfaces A: Physicochemical and Engineering AspectsDual-drug delivery by thermo-responsive Janus nanogel for improved cellular uptake, sustained release, and combination chemo-thermal therapy
2024, International Journal of PharmaceuticsMulti-functional chitosan-based nanoparticles for drug delivery: Recent advanced insight into cancer therapy
2023, Carbohydrate PolymersHyaluronic acid-based drug delivery systems for targeted cancer therapy
2023, Natural Biopolymers in Drug Delivery and Tissue Engineering
- 1
Both authors have equal contribution.